March 20, 2012— Freshmedx today announced that its ground-breaking study on the use of computed bioconductance technology in detecting lung cancer will be published in April edition of the Journal of Thoracic Oncology. Freshmedx’s proprietary CB Test is a non- invasive adjunctive test that can evaluate patients with lesions suspicious for lung cancer and evaluate the likelihood that indeterminate lung lesions are malignant or benign.

“We are pleased to have our clinical results published in the leading lung cancer journal,” said Steve Eror, president and chief executive officer of Freshmedx. “There is an increased need for this technology, especially given the recent National Lung Screening Trial (NLST) results and the adoption of Low-dose helical CT Screening (LDCT) programs.”

In the forthcoming article, Freshmedx describes how the CB Test demonstrated 90% sensitivity and 92% specificity in distinguishing between benign and malignant lesions confirmed by biopsy or stable disease. The article concludes that the non-invasive CB Test may offer novel discrimination between patients with malignant and benign lesions. The article shows that the CB Test may be applied as a first-step risk stratification procedure in the evaluation of indeterminate pulmonary lesions.

Recent results from the National Lung Screening Trial demonstrated that low-dose helical CT screening of high-risk individuals reduced lung cancer deaths by 20% compared to standard chest x-rays. Many healthcare institutions enthusiastic about the NLST results have already adopted low-dose CT screening programs. However, the wide adoption of low-dose CT lung cancer screening programs pose new challenges as these screening programs also trigger many false-positive findings.

According to the International Association for the Study of Lung Cancer Computed Tomography Screening Workshop, “a major risk factor in CT screening is the large number of indeterminate pulmonary lesions that will be detected and may require diagnostic interventions. In the NLST screening trial, the false positivity rate was found to be more than 95%. Inappropriate surgical interventions may put the screened population at risk.”

As LDCT screening programs discover more indeterminate pulmonary nodules, the Freshmedx CB Test described in the Journal of Thoracic Oncology, is uniquely positioned as the ideal adjunctive technology to LDCT. The CB Test can risk stratify these patients to allow quicker therapeutic intervention of lung cancers and defer unnecessary invasive procedures that have potential for patient harm.

The Freshmedx manuscript entitled, “Transcutaneous Computed Bioconductance Measurement in Lung Cancer: a Treatment-Enabling Technology useful for Adjunctive Risk Stratification in the Evaluation of Suspicious Pulmonary Lesions,” which details results of a recently completed clinical trial, is scheduled to be published in the April 2012 edition of the Journal of Thoracic Oncology.

The Journal of Thoracic oncology, the official Journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of thoracic malignancies.

Freshmedx is a private, Utah-based company focused on development, manufacturing, marketing and sales of non-invasive medical diagnostics for life- threatening disease. The testing and devices described in this release are investigational and the related statements have not been approved for marketing by the US FDA.

Media Contact, Public Relations, Catherine Garff
Freshmedx 801-599-5224,

757 East South Temple, Suite 150 Salt Lake City, Utah 84102
U.S.A. Telephone: (801)204.9627